崇達技術(002815.SZ):目前公司收入在美國市場的佔比爲10%左右
格隆匯7月17日丨崇達技術(002815.SZ)於投資者互動平臺表示,目前,公司收入在美國市場的佔比爲10%左右。鑑於當前美國政府對中國加徵關稅政策的頻繁調整,市場供應鏈整體呈現觀望態勢。公司與客戶已建立超過二十年的穩固合作關係,且公司向美國客戶供應的PCB產品主要應用於工業控制領域,該領域產品生命週期通常長達十年,公司在工控領域具備顯著的產品、技術、成本及價格競爭優勢,客戶在短期內難以尋得可替代的優質合適供應商。目前,公司對美銷售訂單接收與產品發貨流程均保持正常運作,未受到較大影響。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.